Cargando…

Non-hemorrhage-related adverse effects of rivaroxaban

The direct oral anticoagulant rivaroxaban is useful in various indications that include venous deep vein thrombosis prophylaxis/treatment after knee/hip replacement surgery and prevention of stroke in patients with non-valvular atrial fibrillation. Its mechanism of action has been mostly associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Christopoulou, Eliza C., Filippatos, Theodosios D., Elisaf, Moses S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777473/
https://www.ncbi.nlm.nih.gov/pubmed/29379891
http://dx.doi.org/10.5114/amsad.2017.72533
_version_ 1783294202683064320
author Christopoulou, Eliza C.
Filippatos, Theodosios D.
Elisaf, Moses S.
author_facet Christopoulou, Eliza C.
Filippatos, Theodosios D.
Elisaf, Moses S.
author_sort Christopoulou, Eliza C.
collection PubMed
description The direct oral anticoagulant rivaroxaban is useful in various indications that include venous deep vein thrombosis prophylaxis/treatment after knee/hip replacement surgery and prevention of stroke in patients with non-valvular atrial fibrillation. Its mechanism of action has been mostly associated with hemorrhage-related adverse effects; thus a number of non-hemorrhage-related adverse effects of the drug have received less attention or go unrecognized. These adverse effects mainly include liver injury, hypersensitivity reactions, leukocytoclastic vasculitis and hair loss. Clinicians should be aware of these rare adverse reactions and advise their patients to contact them as soon as they observe any unexpected clinical response.
format Online
Article
Text
id pubmed-5777473
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-57774732018-01-29 Non-hemorrhage-related adverse effects of rivaroxaban Christopoulou, Eliza C. Filippatos, Theodosios D. Elisaf, Moses S. Arch Med Sci Atheroscler Dis State of the Art Paper The direct oral anticoagulant rivaroxaban is useful in various indications that include venous deep vein thrombosis prophylaxis/treatment after knee/hip replacement surgery and prevention of stroke in patients with non-valvular atrial fibrillation. Its mechanism of action has been mostly associated with hemorrhage-related adverse effects; thus a number of non-hemorrhage-related adverse effects of the drug have received less attention or go unrecognized. These adverse effects mainly include liver injury, hypersensitivity reactions, leukocytoclastic vasculitis and hair loss. Clinicians should be aware of these rare adverse reactions and advise their patients to contact them as soon as they observe any unexpected clinical response. Termedia Publishing House 2017-12-31 /pmc/articles/PMC5777473/ /pubmed/29379891 http://dx.doi.org/10.5114/amsad.2017.72533 Text en Copyright: © 2017 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle State of the Art Paper
Christopoulou, Eliza C.
Filippatos, Theodosios D.
Elisaf, Moses S.
Non-hemorrhage-related adverse effects of rivaroxaban
title Non-hemorrhage-related adverse effects of rivaroxaban
title_full Non-hemorrhage-related adverse effects of rivaroxaban
title_fullStr Non-hemorrhage-related adverse effects of rivaroxaban
title_full_unstemmed Non-hemorrhage-related adverse effects of rivaroxaban
title_short Non-hemorrhage-related adverse effects of rivaroxaban
title_sort non-hemorrhage-related adverse effects of rivaroxaban
topic State of the Art Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777473/
https://www.ncbi.nlm.nih.gov/pubmed/29379891
http://dx.doi.org/10.5114/amsad.2017.72533
work_keys_str_mv AT christopoulouelizac nonhemorrhagerelatedadverseeffectsofrivaroxaban
AT filippatostheodosiosd nonhemorrhagerelatedadverseeffectsofrivaroxaban
AT elisafmosess nonhemorrhagerelatedadverseeffectsofrivaroxaban